Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Novo Nordisk 12.087, Amgen 8.618.
Novo Nordisk vs Amgen Net Worth and Market Cap
Novo Nordisk (NVO) and Amgen (AMGN) are peers in GLP-1. Novo Nordisk reported revenue of $12.1B as of Q2 2026, compared with $8.6B for Amgen. Novo Nordisk leads on revenue.
Novo Nordisk's gross margin is 78.2% versus 68.2% for Amgen. Novo Nordisk's net margin is 26.7% versus 21.1% for Amgen.
Key differences
- Revenue growth on the same quarter a year earlier: Amgen +5.8% (Q1 2026), Novo Nordisk +2.1% (Q2 2026).
- Novo Nordisk's KPIs on Sterling include Next-Generation Obesity: CagriSema + Amycretin Readouts and 2030 Ambitions (Capital Markets Day, 21 Sep 2026).
- Amgen's KPIs on Sterling include AMG 513 Obesity Discontinuation and Cash and Cash Equivalents.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Novo Nordisk, Amgen.| Metric | Novo Nordisk | Amgen |
|---|---|---|
| Market Cap | - | - |
| Revenue | $12.09B | $8.62B |
| Cost of Revenue | $2.63B | $2.74B |
| Gross Profit | $9.45B | $5.87B |
| Operating Income | $4.17B | $2.67B |
| Net Income | $3.23B | $1.82B |
| R&D Expense | $2.74B | $1.72B |
| Earnings Per Share | $0.73 | $3.34 |
| Gross Margin | 78.2% | 68.2% |
| Operating Margin | 34.5% | 30.9% |
| Net Profit Margin | 26.7% | 21.1% |
| Free Cash Flow | $6.53B | $1.48B |
| Cumulative Free Cash Flow | $107.39B | $165.69B |
| Operating Cash Flow | $8.50B | $2.19B |
| Cash & Equivalents | $6.85B | $12.04B |